Sorafenib in combination with transarterial chemoembolization in Chinese patients with hepatocellular carcinoma: A subgroup interim analysis of the START trial

Future Oncology

Volumn 9, Issue 3, 2013, Pages 403-410

  Han, Guohong ^a   Yang, Jijin ^b   Shao, Guoliang ^c   Teng, Gaojun ^d   Wang, Maoqiang ^e   Yang, Jianyong ^f   Liu, Zhaoyu ^g   Feng, Gansheng ^h   Yang, Renjie ⁱ   Lu, Ligong ^j   Chao, Yee ^k   Wang, Jianhua ^l  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c ZHEJIANG CANCER HOSPITAL   (China)

^d SOUTHEAST UNIVERSITY   (China)

^e CHINESE PLA GENERAL HOSPITAL   (China)

^f SUN YAT SEN UNIVERSITY   (China)

^g CHINA MEDICAL UNIVERSITY   (China)

^h HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

ⁱ PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

^j GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^k TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^l FUDAN UNIVERSITY   (China)

more..

Author keywords

hepatocellular carcinoma; sorafenib; transarterial chemoembolization

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA FETOPROTEIN; ASPARTATE AMINOTRANSFERASE; DOXORUBICIN; SORAFENIB;

ADULT; AGED; ALOPECIA; ARTICLE; ASCITES; CANCER COMBINATION CHEMOTHERAPY; CANCER SIZE; CANCER SURVIVAL; CHEMOEMBOLIZATION; CHINESE; COMPUTER ASSISTED TOMOGRAPHY; CONSTIPATION; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG SAFETY; DYSPHAGIA; FATIGUE; FEMALE; GASTROINTESTINAL HEMORRHAGE; HAND FOOT SYNDROME; HEART FAILURE; HUMAN; LIVER CELL CARCINOMA; LIVER FAILURE; LIVER FUNCTION; LIVER INJURY; MAJOR CLINICAL STUDY; MALE; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; SIDE EFFECT; SKIN TOXICITY; TREATMENT DURATION; TREATMENT RESPONSE; UPPER ABDOMINAL PAIN; UPPER GASTROINTESTINAL BLEEDING; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NIACINAMIDE; PHENYLUREA COMPOUNDS; TREATMENT OUTCOME;

EID: 84874928300     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.13.11     Document Type: Article

References (26)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 127, 2893-2917 (2010
2. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 362, 1907-1917 (2003
3. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 42, 1208-1236 (2005
4. Lo CM, Ngan H, Tso WK et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35, 1164-1171 (2002
5. Llovet JM, Real MI, Montana X et al.; Barcelona Liver Cancer Group. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: A randomised controlled trial. Lancet 359, 1734-1739 (2002
6. Llovet JM, Bruix J. Systemic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 37, 429-442 (2003
7. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 379, 1245-1255 (2012
8. Bruix J, Sherman M. Management of hepatocellular carcinoma: An update. Hepatology 53, 1020-1022 (2011
9. Llovet JM. Updated treatment approach to hepatocellular carcinoma. J. Gastroenterol. 40, 225-235 (2005
10. Li X, Feng G-S, Zheng C-S, Zhuo C-K, Liu X. Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level. World J. Gastroenterol. 10, 2878-2882 (2004
11. Wang B, Xu H, Gao ZQ, Ning HF, Sun YQ, Cao GW. Increased expression of vascular endothelial growth factor in hepatocellular carcinoma after transcatheter arterial chemoembolization. Acta Radiol. 49, 523-529 (2008
12. Fernández M, Semela D, Bruix J et al. Angiogenesis in liver disease. J. Hepatol. 50, 604-620 (2009
13. Llovet JM, Ricci S, Mazzaferro V et al.; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359, 378-390 (2008
14. Cheng AL, Kang YK, Chen Z et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A Phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 10, 25-34 (2009
15. Wilhelm SM, Carter C, Tang L et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 64, 7099-7109 (2004
16. Chang YS, Adnane J, Trail PA et al. Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models. Cancer Chemother. Pharmacol. 59, 561-574 (2007
17. Ito Y, Sasaki Y, Horimoto M et al. Activation of mitogen-Activated protein kinases/extracellular signal-regulated kinases in human hepatocellular carcinoma. Hepatology 27, 951-958 (1998
18. Villanueva A, Newell P, Chiang DY, Friedman SL, Llovet JM. Genomics and signaling pathways in hepatocellular carcinoma. Semin. Liver Dis. 27, 55-76 (2007
19. Semela D, Dufour JF. Angiogenesis and hepatocellular carcinoma. J. Hepatol. 41, 864-880 (2004
20. Chao Y, Lee HC, Lee TY et al. START (Study in Asia of the Combination of TACE (transcatheter arterial chemoembolization) with Sorafenib in Patients with Hepatocellular Carcinoma) Trial. 5th International Liver Cancer Association (ILCA) Annual Conference. Wanchai, Hong Kong. 1-3 September 2011 (Abstract 0-026
21. European Association for the Study of the Liver; European Organisation for Research and Treatment of Cancer. EASL-EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma. J. Hepatol. 56(4), 908-943 (2012
22. Marelli L, Stigliano R, Triantos C et al. Transarterial therapy for hepatocellular carcinoma: Which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc. Intervent. Radiol. 30, 6-25 (2007
23. Takayasu K, Arii S, Ikai I et al.; Liver Cancer Study Group of Japan. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology 131, 461-469 (2006
24. Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N. Engl. J. Med. 332, 1256-1261 (1995
25. Pawlik TM, Reyes DK, Cosgrove D, Kamel IR, Bhagat N, Geschwind JF. Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma. J. Clin. Oncol. 29, 3960-3967 (2011
26. Cabrera R, Pannu DS, Caridi J et al. The combination of sorafenib with transarterial chemoembolisation for hepatocellular carcinoma. Aliment. Pharmacol. Ther. 34, 205-213 (2011